

CITATION REPORT

List of articles citing

Drug-drug interactions of non-vitamin K oral anticoagulants

DOI: 10.1080/17425255.2016.1225037

Expert Opinion on Drug Metabolism and Toxicology,
2016, 12, 1445-1461.

Source: <https://exaly.com/paper-pdf/64519295/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2017 , 33, 345-367	1.5	93
31	Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs. <i>Drug Safety</i> , 2017 , 40, 1091-1098	5.1	7
30	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018 , 36, 624-632	1.3	36
29	Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2018 , 131, 573.e1-573.e8	2.4	13
28	Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. <i>Frontiers in Neurology</i> , 2018 , 9, 1067	4.1	43
27	The Evolution of Lung Transplant Immunosuppression. <i>Drugs</i> , 2018 , 78, 965-982	12.1	16
26	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2018 , 9, 575	5.6	12
25	Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 381-398	5.5	21
24	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 345-352	5.1	8
23	The Basics of Antithrombotic Medications. <i>Topics in Geriatric Rehabilitation</i> , 2019 , 35, 55-71	0.7	
22	Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients. <i>American Journal of Cardiovascular Drugs</i> , 2019 , 19, 195-201	4	4
21	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 294-303	5.1	14
20	Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 31-44	5.5	14
19	Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. <i>JAMA Internal Medicine</i> , 2020 , 180, 1052-1060	11.5	16
18	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1150-1164	3.8	22
17	P2Y inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. <i>Heart</i> , 2020 , 106, 575-583	5.1	8
16	Encyclopedia of Molecular Pharmacology. 2021 , 1-18		

15	Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 1110-1116	5.1	1
14	Prescribing of two potentially interacting cardiovascular medications in atrial fibrillation patients on direct oral anticoagulants. <i>IJC Heart and Vasculature</i> , 2021 , 34, 100788	2.4	1
13	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2068-2081	15.4	5
12	Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4482	1.3	
11	2018 EHRA Practical Guide, Rationale, History and Experience. <i>European Journal of Arrhythmia & Electrophysiology</i> , 2018 , 4, 43	0.3	
10	Importance des interactions médicamenteuses nées chez le patient oncologique : comparaison de programmes de d'ection informatisé. <i>Douleur Et Analgesie</i> , 2019 , 32, 21-36	0.2	
9	Outcomes of Direct Oral Anticoagulants Co-Prescribed with Common Interacting Medications. <i>American Journal of Cardiology</i> , 2021 ,	3	0
8	Encyclopedia of Molecular Pharmacology. 2021 , 560-577		
7	Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 819878	5.6	1
6	Table_1.DOCX. 2018 ,		
5	Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. <i>Thrombosis Research</i> , 2022 , 213, S66-S71	8.2	1
4	Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors. <i>JAMA Network Open</i> , 2022 , 5, e2219128	10.4	1
3	Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients.		0
2	Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. 2023 , 186, 58-65		0
1	Direct Oral Anticoagulants. An Updated Systematic Review of its Clinical Pharmacology and Clinical Effectiveness and Safety in Patients with Nonvalvular Atrial Fibrillation.		0